Operating Income (Loss) of Pharma-Bio Serv, Inc. from 31 Jul 2010 to 31 Oct 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Pharma-Bio Serv, Inc. quarterly and annual Operating Income (Loss) in USD history and change rate from 31 Jul 2010 to 31 Oct 2025.
  • Pharma-Bio Serv, Inc. Operating Income (Loss) for the quarter ending 31 Oct 2025 was $133,272, a 14% increase year-over-year.
  • Pharma-Bio Serv, Inc. Operating Income (Loss) for the twelve months ending 31 Oct 2025 was $637,662, a 50% increase year-over-year.
  • Pharma-Bio Serv, Inc. annual Operating Income (Loss) for 2025 was $637,662, a 50% increase from 2024.
  • Pharma-Bio Serv, Inc. annual Operating Income (Loss) for 2024 was $1,287,587, a 215% decline from 2023.
  • Pharma-Bio Serv, Inc. annual Operating Income (Loss) for 2023 was $1,117,411, a 4.9% decline from 2022.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Pharma-Bio Serv, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $637,662 $133,272 +$20,858 +14% 01 Aug 2025 31 Oct 2025 10-K 29 Jan 2026 2025 FY
Q2 2025 $658,520 $313,877 +$67,905 +18% 01 May 2025 31 Jul 2025 10-Q 15 Sep 2025 2025 Q3
Q1 2025 $726,425 $98,322 +$215,053 +69% 01 Feb 2025 30 Apr 2025 10-Q 16 Jun 2025 2025 Q2
Q4 2024 $941,478 $92,191 +$346,109 +79% 01 Nov 2024 31 Jan 2025 10-Q 17 Mar 2025 2025 Q1
Q3 2024 $1,287,587 $154,130 -$102,365 -198% 01 Aug 2024 31 Oct 2024 10-K 29 Jan 2026 2025 FY
Q2 2024 $1,185,222 $381,782 -$842,248 -183% 01 May 2024 31 Jul 2024 10-Q 15 Sep 2025 2025 Q3
Q1 2024 $342,974 $313,375 -$693,453 -182% 01 Feb 2024 30 Apr 2024 10-Q 16 Jun 2025 2025 Q2
Q4 2023 $350,479 $438,300 -$766,932 -233% 01 Nov 2023 31 Jan 2024 10-Q 17 Mar 2025 2025 Q1
Q3 2023 $1,117,411 $51,765 -$220,727 -131% 01 Aug 2023 31 Oct 2023 10-K 29 Jan 2025 2024 FY
Q2 2023 $1,338,138 $460,466 +$90,961 +25% 01 May 2023 31 Jul 2023 10-Q 16 Sep 2024 2024 Q3
Q1 2023 $1,247,177 $380,078 +$99,448 +35% 01 Feb 2023 30 Apr 2023 10-Q 14 Jun 2024 2024 Q2
Q4 2022 $1,147,729 $328,632 -$27,216 -7.6% 01 Nov 2022 31 Jan 2023 10-Q 18 Mar 2024 2024 Q1
Q3 2022 $1,174,945 $168,962 +$4,967,046 01 Aug 2022 31 Oct 2022 10-K 29 Jan 2024 2023 FY
Q2 2022 $3,792,101 $369,505 +$9,015 +2.5% 01 May 2022 31 Jul 2022 10-Q 14 Sep 2023 2023 Q3
Q1 2022 $3,801,116 $280,630 +$15,851 +6% 01 Feb 2022 30 Apr 2022 10-Q 14 Jun 2023 2023 Q2
Q4 2021 $3,816,967 $355,848 +$36,727 +12% 01 Nov 2021 31 Jan 2022 10-Q 17 Mar 2023 2023 Q1
Q3 2021 $3,853,694 $4,798,084 -$4,949,798 -3263% 01 Aug 2021 31 Oct 2021 10-K 30 Jan 2023 2022 FY
Q2 2021 $1,096,104 $360,490 -$456,200 -56% 01 May 2021 31 Jul 2021 10-Q 14 Sep 2022 2022 Q3
Q1 2021 $1,552,304 $264,779 -$455,605 -63% 01 Feb 2021 30 Apr 2021 10-Q 14 Jun 2022 2022 Q2
Q4 2020 $2,007,909 $319,121 -$217,638 -41% 01 Nov 2020 31 Jan 2021 10-Q 17 Mar 2022 2022 Q1
Q3 2020 $2,225,547 $151,714 -$236,325 -61% 01 Aug 2020 31 Oct 2020 10-K 11 Feb 2022 2021 FY
Q2 2020 $2,461,872 $816,690 +$455,994 +126% 01 May 2020 31 Jul 2020 10-Q 14 Sep 2021 2021 Q3
Q1 2020 $2,005,878 $720,384 +$243,456 +51% 01 Feb 2020 30 Apr 2020 10-Q 14 Jun 2021 2021 Q2
Q4 2019 $1,762,422 $536,759 +$65,739 +14% 01 Nov 2019 31 Jan 2020 10-Q 17 Mar 2021 2021 Q1
Q3 2019 $1,696,683 $388,039 -$109,403 -22% 01 Aug 2019 31 Oct 2019 10-K 01 Feb 2021 2020 FY
Q2 2019 $1,806,086 $360,696 -$361,123 -50% 01 May 2019 31 Jul 2019 10-Q 14 Sep 2020 2020 Q3
Q1 2019 $2,167,209 $476,928 +$485,611 01 Feb 2019 30 Apr 2019 10-Q 15 Jun 2020 2020 Q2
Q4 2018 $1,681,598 $471,020 +$2,943,334 01 Nov 2018 31 Jan 2019 10-Q 16 Mar 2020 2020 Q1
Q3 2018 $1,261,736 $497,442 +$372,441 +298% 01 Aug 2018 31 Oct 2018 10-K 29 Jan 2020 2019 FY
Q2 2018 $1,634,177 $721,819 +$916,073 01 May 2018 31 Jul 2018 10-Q 16 Sep 2019 2019 Q3
Q1 2018 $2,550,250 $8,683 +$315,885 +97% 01 Feb 2018 30 Apr 2018 10-Q 14 Jun 2019 2019 Q2
Q4 2017 $2,866,135 $2,472,314 -$2,088,317 -544% 01 Nov 2017 31 Jan 2018 10-Q 18 Mar 2019 2019 Q1
Q3 2017 $777,818 $125,001 +$574,759 01 Aug 2017 31 Oct 2017 10-K 29 Jan 2019 2018 FY
Q2 2017 $1,352,577 $194,254 -$73,468 -61% 01 May 2017 31 Jul 2017 10-Q 14 Sep 2018 2018 Q3
Q1 2017 $1,279,109 $324,568 -$419,205 -443% 01 Feb 2017 30 Apr 2017 10-Q 14 Jun 2018 2018 Q2
Q4 2016 $859,904 $383,997 -$768,145 -200% 01 Nov 2016 31 Jan 2017 10-Q 19 Mar 2018 2018 Q1
Q3 2016 $91,759 $449,758 -$1,015,344 -180% 01 Aug 2016 31 Oct 2016 10-K 29 Jan 2018 2017 FY
Q2 2016 $923,585 $120,786 -$616,108 -124% 01 May 2016 31 Jul 2016 10-Q 14 Sep 2017 2017 Q3
Q1 2016 $1,539,693 $94,637 -$297,355 -76% 01 Feb 2016 30 Apr 2016 10-Q 14 Jun 2017 2017 Q2
Q4 2015 $1,837,048 $384,148 +$55,704 +17% 01 Nov 2015 31 Jan 2016 10-Q 17 Mar 2017 2017 Q1
Q3 2015 $1,781,344 $565,586 -$353,420 -38% 01 Aug 2015 31 Oct 2015 10-K 31 Jan 2017 2016 FY
Q2 2015 $2,134,764 $495,322 -$202,938 -29% 01 May 2015 31 Jul 2015 10-Q 14 Sep 2016 2016 Q3
Q1 2015 $2,337,702 $391,992 -$27,271 -6.5% 01 Feb 2015 30 Apr 2015 10-Q 14 Jun 2016 2016 Q2
Q4 2014 $2,364,973 $328,444 -$499,176 -60% 01 Nov 2014 31 Jan 2015 10-Q 16 Mar 2016 2016 Q1
Q3 2014 $2,864,149 $919,006 -$581,265 -39% 01 Aug 2014 31 Oct 2014 10-K 29 Jan 2016 2015 FY
Q2 2014 $3,445,414 $698,260 -$835,165 -54% 01 May 2014 31 Jul 2014 10-Q 14 Sep 2015 2015 Q3
Q1 2014 $4,280,579 $419,263 -$1,328,451 -76% 01 Feb 2014 30 Apr 2014 10-Q 15 Jun 2015 2015 Q2
Q4 2013 $5,609,030 $827,620 -$462,684 -36% 01 Nov 2013 31 Jan 2014 10-Q 17 Mar 2015 2015 Q1
Q3 2013 $6,071,714 $1,500,271 +$127,079 +9.3% 01 Aug 2013 31 Oct 2013 10-K 29 Jan 2015 2014 FY
Q2 2013 $5,944,635 $1,533,425 -$39,241 -2.5% 01 May 2013 31 Jul 2013 10-Q 15 Sep 2014 2014 Q3
Q1 2013 $5,983,876 $1,747,714 +$321,901 +23% 01 Feb 2013 30 Apr 2013 10-Q 16 Jun 2014 2014 Q2
Q4 2012 $5,661,975 $1,290,304 -$71,641 -5.3% 01 Nov 2012 31 Jan 2013 10-Q 17 Mar 2014 2014 Q1
Q3 2012 $5,733,616 $1,373,192 +$343,055 +33% 01 Aug 2012 31 Oct 2012 10-K 29 Jan 2014 2013 FY
Q2 2012 $5,390,561 $1,572,666 +$405,087 +35% 01 May 2012 31 Jul 2012 10-Q 16 Sep 2013 2013 Q3
Q1 2012 $4,985,474 $1,425,813 +$689,058 +94% 01 Feb 2012 30 Apr 2012 10-Q 14 Jun 2013 2013 Q2
Q4 2011 $4,296,416 $1,361,945 +$844,418 +163% 01 Nov 2011 31 Jan 2012 10-Q 18 Mar 2013 2013 Q1
Q3 2011 $3,451,998 $1,030,137 01 Aug 2011 31 Oct 2011 10-K 29 Jan 2013 2012 FY
Q2 2011 $1,167,579 +$962,820 +470% 01 May 2011 31 Jul 2011 10-Q 14 Sep 2012 2012 Q3
Q1 2011 $736,755 01 Feb 2011 30 Apr 2011 10-Q 14 Jun 2012 2012 Q2
Q4 2010 $517,527 01 Nov 2010 31 Jan 2011 10-Q 16 Mar 2012 2012 Q1
Q2 2010 $204,759 01 May 2010 31 Jul 2010 10-Q 14 Sep 2011 2011 Q3

Pharma-Bio Serv, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $637,662 +$649,925 +50% 01 Nov 2024 31 Oct 2025 10-K 29 Jan 2026 2025 FY
2024 $1,287,587 -$2,404,998 -215% 01 Nov 2023 31 Oct 2024 10-K 29 Jan 2026 2025 FY
2023 $1,117,411 -$57,534 -4.9% 01 Nov 2022 31 Oct 2023 10-K 29 Jan 2025 2024 FY
2022 $1,174,945 +$5,028,639 01 Nov 2021 31 Oct 2022 10-K 29 Jan 2024 2023 FY
2021 $3,853,694 -$6,079,241 -273% 01 Nov 2020 31 Oct 2021 10-K 30 Jan 2023 2022 FY
2020 $2,225,547 +$528,864 +31% 01 Nov 2019 31 Oct 2020 10-K 11 Feb 2022 2021 FY
2019 $1,696,683 +$2,958,419 01 Nov 2018 31 Oct 2019 10-K 01 Feb 2021 2020 FY
2018 $1,261,736 -$483,918 -62% 01 Nov 2017 31 Oct 2018 10-K 29 Jan 2020 2019 FY
2017 $777,818 -$686,059 -748% 01 Nov 2016 31 Oct 2017 10-K 29 Jan 2019 2018 FY
2016 $91,759 -$1,873,103 -105% 01 Nov 2015 31 Oct 2016 10-K 29 Jan 2018 2017 FY
2015 $1,781,344 -$1,082,805 -38% 01 Nov 2014 31 Oct 2015 10-K 31 Jan 2017 2016 FY
2014 $2,864,149 -$3,207,565 -53% 01 Nov 2013 31 Oct 2014 10-K 29 Jan 2016 2015 FY
2013 $6,071,714 +$338,098 +5.9% 01 Nov 2012 31 Oct 2013 10-K 29 Jan 2015 2014 FY
2012 $5,733,616 +$2,281,618 +66% 01 Nov 2011 31 Oct 2012 10-K 29 Jan 2014 2013 FY
2011 $3,451,998 +$2,842,108 +466% 01 Nov 2010 31 Oct 2011 10-K 29 Jan 2013 2012 FY
2010 $609,890 01 Nov 2009 31 Oct 2010 10-K/A 31 Jan 2012 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.